In the quest to treat cancer and other systemic diseases, researchers have designed increasingly sophisticated "smart" delivery vehicles—nanoparticles, liposomes, and engineered viruses. Yet, a sobering reality persists: in the vast majority of cases, less than 1% of the administered dose actually reaches the target tissue.
This efficiency bottleneck is not merely a failure of targeting ligands. Instead, it is the result of a fundamental conflict between synthetic medicine and the body’s innate defense mechanisms, primarily the Mononuclear Phagocyte System (MPS).
The Biological Sink
When a therapeutic agent is injected intravenously, it does not travel through a neutral pipe. It enters a highly reactive biological environment. The liver and spleen act as a massive biological filter, or "sink," designed to identify and remove foreign matter from the bloodstream.
As Yuling Xiao and Weibo Cai have noted, even platforms with high-affinity targeting ligands, such as gold nanorods or integrin-tracking probes, are frequently sequestered by the reticuloendothelial system (RES) before they can ever interact with a tumor receptor Gold Nanorods Conjugated with Doxorubicin and cRGD for Combined Anticancer Drug Delivery and PET Imaging.
This sequestration is driven by specialized macrophages in the liver (Kupffer cells) that recognize and engulf nanoparticles within minutes. The result is a dramatic reduction in the "therapeutic window"—the time the drug circulates at a concentration high enough to be effective. According to Xixi Wu and Shuangqi Yu, this biological barrier is the primary reason why systemic delivery efficiency for solid tumors and glioblastomas remains stubbornly below the one percent threshold Biopolymer-Based Nanomedicine for Cancer Therapy: Opportunities and Challenges.
The Neutralization Barrier for Biologics
The problem extends beyond synthetic particles to biological agents like oncolytic viruses. While these viruses are engineered to replicate only in cancer cells, the host’s immune system cannot distinguish a "therapeutic" virus from a pathogen.
Guodong Cao and Hui Dong highlight that innate and adaptive immune responses—specifically neutralizing antibodies—rapidly clear these agents from circulation The Oncolytic Virus in Cancer Diagnosis and Treatment. This often forces clinicians to rely on direct intratumoral injections, which are technically difficult for deep-seated or metastatic lesions, because intravenous delivery simply cannot bypass the immune gauntlet Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages.
Strategies for Evasion and Blockade
To move past the 1% barrier, research has shifted from "better targeting" to "better evasion." Several mechanisms have emerged to distract or bypass the MPS:
1. MPS Blockade and Decoys
Rather than making the therapeutic particle invisible, researchers like Pingping Feng have experimented with "blocker" liposomes. By injecting a decoy that saturates the liver's clearance capacity just before the actual drug, they can extend the circulation time of the therapeutic payload by over two-fold Mononuclear phagocyte system blockade for enhanced liposome-assisted metabolic glycan labeling and circulating biomarker detection in mice.
2. Biomimetic Cloaking
Another approach involves "hiding in plain sight." Xiaodong Zhuang developed vesicles encapsulated in leukemia cell membranes to bypass immune detection Artificial cell vesicle-mediated delivery of Catharanthus roseus (L.) G. Don-derived vinca alkaloids for enhanced antitumor efficacy. Similarly, Sheng Li demonstrated "RBC-hitchhiking," where nanoparticles are adsorbed onto the surface of red blood cells to leverage their natural circulatory path and avoid macrophage uptake RBC-hitchhiking PLGA nanoparticles loading β-glucan as a delivery system to enhance in vitro and in vivo immune responses in mice.
3. Genetic Re-engineering
For viral vectors, the solution may lie in genetic modification. Yafeng Lv successfully re-engineered Adeno-associated viruses (AAVs) to ignore their natural "homing" instinct for the liver, redirecting them toward breast cancer cells and reducing off-target toxicity Gene delivery to breast cancer by incorporated EpCAM targeted DARPins into AAV2.
Why Intuition Matters
The shift in this field is a move from a pharmacokinetic view (how much drug is in the blood) to a physiological view (how the body’s filtration systems interact with the drug). As Astrid Gasselhuber points out, mathematical models that fail to account for macrophage uptake will always overestimate drug efficacy Comparison of Conventional Chemotherapy, Stealth Liposomes and Temperature-Sensitive Liposomes in a Mathematical Model. Understanding the MPS as a dynamic barrier rather than a static obstacle is the key to unlocking the next generation of nanomedicine.